Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022
August 22, 2022 at 07:16 pm
Share
Rasna Therapeutics, Inc. reported earnings results for the third quarter and nine months ended June 30, 2022. For the third quarter, the company reported net loss was USD 0.646423 million compared to USD 0.12359 million a year ago. Basic loss per share from continuing operations was USD 0.01.
For the nine months, net loss was USD 0.627064 million compared to USD 0.561812 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
ACTAVIA LIFE SCIENCES, INC. 
